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ABSTRACT 
While a large body of research has formally identified 
apolipoprotein E (APOE) as a major genetic risk marker for 
Alzheimer’s disease, accumulating evidence supports the 
notion that other risk markers may exist. The traditional 
Alzheimer’s-specific signature analysis methods, however, 
have not been able to make full use of rich protein expression 
data, especially the interaction between attributes. This paper 
develops a novel feature selection method to identify 
pathogenic factors of Alzheimer’s disease using the proteomic 
and clinical data. This approach has taken the weights of 
network nodes as the importance order of signaling protein 
expression values. After generating and evaluating the 
candidate subset, the method helps to select an optimal subset 
of proteins that achieved an accuracy greater than 90%, which 
is superior to traditional machine learning methods for clinical 
Alzheimer’s disease diagnosis. Besides identifying a proteomic 
risk marker and further reinforce the link between metabolic 
risk factors and Alzheimer’s disease, this paper also suggests 
that apidonectin-linked pathways are a possible therapeutic 
drug target. 
CCS CONCEPTS 
• Computing methodologies • Machine learning • Learning 
paradigms • Supervised learning • Supervised learning by 
classification 
KEYWORDS 
Feature selection, Deep belief network, Alzheimer’s disease, 
Proteomic risk markers, ACRP30 
1 Introduction 
Alzheimer’s disease (AD) is a common form of 
neurodegenerative disease that is estimated to affect 131 
million people worldwide by 2050 [1]. AD accounts for 60% to 
70% of cases in all dementia diseases [2, 3], and it can progress 
for years before symptoms become detectable by conventional 
means. One approach categorizes AD into two subtypes 
according to the age at onset: early-onset AD and late-onset AD. 
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Approximately 60% of early-onset AD (EOAD) cases have a 
history of multiple family members with AD. There are 13% of 
these cases having autosomal dominant manners. That affects 
at least three generations [4, 5]. Except for several families with 
single-gene disorders, most of them present complex situations 
caused by multiple susceptibility genes and environmental 
factors. [6-8]. Late-onset AD (LOAD) is a prevalent disease of 
which the onset age is older than 60 or 65 years. In general, 
Overall, more than 90% of AD patients are sporadic cases that 
belong to LOAD [9]. Studies have shown that there is a genetic 
factor in LOAD, but no study has identified any causative gene. 
Indeed, many genetic studies have consistently linked the APOE 
gene to sporadic LOAD [10-14]. There are other unidentified 
genetic or environmental factors, as many people with the 
APOE risk allele (ε4) live into their 90s. 
Diagnostic markers should have the ability to reflect 
pathogenic processes of the AD, including the degeneration of 
the neurons and synapses [15]. Some studies have identified 
tau and the 42 amino acid β-amyloid peptide (Aβ42) that met 
this criterion using traditional methods [16-18]. Variance 
analysis can compare the differences between AD cases and 
healthy controls. The Pearson correlation coefficient is 
computed to assess the correlation between markers and AD. 
Researchers have calculated sensitivity and specificity by the 
cutoff value to reflect the proportion of patients with different 
indicators [19]. These studies, however, require long-term 
follow-up for clinical neurochemical analyses and assay these 
two markers weekly. The process is notably time-consuming 
and complicated. There is a great need for a more effective way 
to evaluate the diagnostic potential of proteins. 
Recently researchers have focused on the development of 
diagnostic tools for AD [20,55]. The analysis of multiple image 
modalities is the primary means to understand the 
pathogenesis and identify the diagnostic markers of AD. For 
example, researchers have made valuable findings on Magnetic 
Resonance Imaging (MRI) [21], Positron Emission Tomography 
(PET) [22], and functional MRI (fMRI) [23]. Several studies 
have investigated a few Cerebrospinal Fluid (CSF) proteins [24]. 
Fewer studies have involved serum proteins [25] and using 
both CSF and serum proteins [26]. Although researchers have 
worked on improving diagnostic methods over the last several 
decades, there is still a great need for a fully automated and less 
subjective method that could detect the disease at earlier stages. 
This paper deployed a deep belief network (DBN) based 
method for AD diagnosis using 120 signaling proteins data. 
Identifying useful risk markers plays a vital role in 
determining AD, especially those markers that are detectable in 
the early stage of the disease. It helps in early intervention to 
prevent neurodegeneration. Also, during the intervention 
process, the real-time testing of these markers can help to 
evaluate the effect of the intervention. Identifying the genes 
responsible for complex diseases can be very challenging. The 
most significant limitation of the traditional biological 
identification methods is the scalability of unique targets. The 
traditional methods depend on a priori determined hypotheses 
of different biological significance. There are also statistical 
methods to identify potential diagnostic biomarkers. Eric 
Nagele [27] evaluated the differential significance of each 
biomarker and selected ten autoantibody biomarkers that 
could effectively differentiate AD, but they did not explain the 
biological mechanisms that could account for the findings and 
need to verify the prediction accuracy by constructing other 
models.  
In contrast, the proposed method could select biomarkers 
that maximize disease diagnosis simultaneously in an 
automated approach. The proposed method is also able to 
identify pathogenic factors that are biologically significant, an 
important breakthrough in understanding the underlying 
pathology. There is a study that formulizes biomarker 
identification from signaling proteins expression data as a 
feature selection problem [28]. In this context, the purpose is to 
select a group of proteins that is most effective in diagnosing 
AD. Yang and others consider this problem, and various search 
strategies could be applied [29]. Besides the capability of 
dimensional reduction, the improvement of feature selection 
methods is in need of other aspects, including interpretability, 
time efficiency, and generalization ability [30]. 
Researchers have categorized the feature selection methods 
into filter-based methods, wrapper-based methods, and 
embedded-based methods, according to how to combine 
feature search with classification tasks. Filter methods evaluate 
each feature separately and ignore their interaction. Besides, 
the feature importance assessment is independent of the 
classification task. Chaves proposed a filter-based method 
based on association rule mining algorithm for AD [31]. 
Computing the correlation between features and labels can 
help select features in classification tasks. The valuable features 
are highly correlated with the label while weakly correlated 
with other features. As a commonly used measure, Spearman’s 
correlation coefficient assesses the degree of correlation 
between the two features. 
Traditional machine learning methods focus on a shallow 
learning structure that contains only nonlinear transformation. 
The caveat of the shallow structure is that it cannot represent 
complex functions, which is limited by sample size and a 
calculation unit. The complexity of complex classification 
problems further limits its generalization capacity. There is a 
need to demonstrate that the non-independence feature 
representation leads to a better feature set. Neuroscience 
research has shown that the human visual system uses a multi-
layered system for information processing. This clear hierarchy 
for human perception dramatically reduces the complexity of 
data processing in the visual system and retains the useful 
information of the object structure. The success of machine 
learning largely depends on data representation. Learning 
representations of the data help extract useful information for 
classification tasks. These learned representations reveal the 
nature of the data and can be migratable to other tasks [32]. 
The practical and theoretical experiences tell us that it is 
beneficial to use deep architecture to learn complex functions 
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that can represent high-level abstractions. Recently, deep 
learning-based methods have achieved better performance 
than other methods for many applications, but little work has 
utilized it for AD prediction with protein expression data.  
Despite numerous studies identifying other AD genetic risk 
factors, APOE [33, 34] remains the best predictive gene of AD 
for which there is a scientific consensus. Previous biological 
studies have hypothesized that adiponectin is also possibly 
related to AD [35]. This paper proposes a novel feature 
selection method based on multiple levels of data 
representation and ranking the feature based on the weights of 
the deep network. ACRP30 is a protein that is encoded by the 
ADIPOQ gene in which mutations have been associated with 
adiponectin deficiency. This paper seeks to determine whether 
ACRP30 is a potential risk marker for AD diagnosis. 
Furthermore, we examine whether the proposed deep learning 
framework can achieve diagnostic accuracy comparable to that 
of more widely used methods.  
2 Proposed method 
This paper considers the AD diagnosis as a classification 
problem. The objective is to judge the cognitive status of people 
according to their signaling protein expression values. This 
paper proposes a method for disease diagnosis using Deep 
Belief Network (DBN), which is a probabilistic generative 
neural network consisting of multiple layers of Restricted 
Boltzmann Machine (RBM). The preferable performance of 
DBNs is partly due to the stochastic nature of RBM. This 
machine could encapsulate a form of robustness to corruption 
in the representations that DBNs can learn despite the noise 
during training. A DBN satisfies the good intermediate 
representation criterion, that is, robustness to the partial 
destruction of the input [31]. For identifying the proteomic risk 
marker, this paper also proposed a belief network-based 
feature selection method using the weights of the network to 
indicate the importance of the features.  
2.1 AD diagnosis 
As shown in Figure 1, the input data consists of 120 protein 
expression values that measured from 90 AD cases and 90 non-
demented controls (NDC). A DBN model uses this input data as 
the training dataset. The hidden layer aims to reduce the 
dimension of the raw data and learn a better representation of 
the features hidden in the inputs. This model can be useful for 
any feature extraction task, including biological data, as well as 
those with classes that are not linearly separable. 
 
Figure 1: The proposed framework for AD diagnosis. 
After training the DBN, the proposed method uses the 
learned weights to initialize a back-propagation neural 
network (BPNN) for AD diagnosis. BPNN is a multi-layer 
feedforward network that adopted an error backpropagation 
training algorithm. It learns and stores many mappings 
between input-output models without prior mathematic 
equations that describe this mapping. The learning rule used to 
adjust the weights and thresholds is the steepest descent 
method. 
This paper interests in two tasks with this model. The first 
task is to predict whether the participants diagnosed with AD 
is associated with a particular set of genomic features, such as 
gene expression data. The method created the training dataset 
with two classes, where 0.9 and 0.1 indicate AD and NDC 
respectively, rather than 1 and 0 given the sigmoid activation 
function. 
In the field of machine learning, most methods use learned 
features to realize their unique targets. These features have no 
direct relations with the originals. In the era of big biological 
data, there is an urgent need for effective dimension reduction 
methods that can form characteristics by selecting the given 
input attributes. These methods can extract key factors and 
reduce the necessary number of indexes to solve the problems. 
When the training process completes, the weight of the 
nodes connected each layer on behalf of the contribution to the 
activation values of upper layer nodes. According to the sum of 
the absolute value of weights connected input nodes and all 
nodes in the upper layer, one can choose more important input 
nodes subsequently. Therefore, this paper adjusts the threshold 
variably to select a smaller subset of plasma signaling proteins 
on which the methods could achieve comparative disease 
diagnostic accuracy. 
2.2 DBN-based feature selection for 
identifying proteomic risk marker 
This paper proposes a six-step feature selection method based 
on a designed feature importance criterion and a method for 
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constructing candidate feature subsets. Table 1 describes the 
details of the algorithm. The weights of the nodes in the input 
layer and the hidden layer of the trained model serve to 
indicate the importance of protein expression values in AD 
diagnosis. After ranking the importance of proteins, important 
ones are selected in turn to construct candidate feature subsets. 
The AD prediction method is trained on them to form new 
models. The performance of these models on different feature 
subsets is compared by 10-fold cross-validation. The algorithm 
selects the optimal feature subset that gives the model the 
highest AD diagnosis performance. At the expense of additional 
computational burden, the whole procedure can repeat 
multiple times (in an outer cross-validation loop) to reduce the 
variance of performance prediction. Extensive experiments 
show that such an algorithm works well in practice. The 
training time is tolerable of the compact network size. The 
experiments suggest that the performance can be improved 
simply by waiting for bigger datasets to become available. 
Table 1. The proposed feature selection method. 
Input: 
Dataset G={X, Y} consists of a sample with protein 
expression values and label 
Output: Feature subset that contains k features 
Step 1 Data preparation 
 
Divide the dataset G into training dataset {Xtrain, 
Ytrain}, and testing dataset {Xtrain, Ytrain}. Xtrain is a 
matrix in which a column Xi represents the 
protein expression values of the ith protein in all 
samples. Ytrain is the label indicating the cognitive 
status of samples. 
Step 2 Feature importance criterion  
 
Choose the weights between input nodes and 
hidden nodes of the proposed model as the 
feature importance criterion R(Xi, Y), 1≤i≤N. N 
is the total number of proteins. 
Step 3 Optimal model selection 
 
Train DBN model on the training dataset, 
Initialize the NN with the parameters of DBN,  
Train the NN on the training dataset and adjust 
the hyperparameters to obtain the best AD 
diagnosis performance 
Step 4 Candidate feature subset construction 
 
Sort the features based on the feature importance 
criterion:  
R(Xr1,Y)≤R(Xr2,Y) ≤…≤R(XrN-1,Y) ≤R(XrN,Y) 
and construct candidate feature subsets S={S1, 
S2,…, SN}, in which S1={Xr1}, S2={Xr1, Xr2},…, 
SN={ Xr1, Xr2,…, XrN-1, XrN}. 
Step 5 Optimal feature subset identification   
 
For each j, 1≤j≤N, 
Train the NN-based model on feature subset Si 
using 10-fold cross-validation. 
Record the accuracy ACC(j) of the model. 
End 
Select the smallest feature set Soptimal that has the 
highest accuracy. 
Step 6 Optimal feature subset evaluation 
 
Train the NN-based model on the training 
dataset using the feature subset Soptimal 
Test its performance on the testing dataset. 
The causes of AD are still unknown but might have some 
connection with genes related to cholesterol [56]. This paper 
fully considers this possibility, and constructs a more compact 
deep architecture with a smaller number of hidden nodes. This 
architecture ensures that each hidden unit has a similar impact 
on the output layer. After training the network, this paper picks 
out the most crucial attribute of the inputs whose weights to 
the second hidden layer are the largest. In other words, it is the 
gene most relevant to AD within the scope of the candidate. 
3 Results 
3.1 Dataset 
The dataset contains the expression values of 120 blood plasma 
proteins from 259 plasma samples of AD cases and non-
demented controls (NDC). Filter-based arrayed sandwich 
enzyme-linked immunosorbent assay is used to collect these 
values [38]. One can download the dataset from 
http://www.nature.com/nm/journal/v13/n11/suppinfo/nm
1653_S1.html.  
3.2 Experimental settings 
This section presents the experimental settings and results in 
the AD prediction and feature selection. It carries out 5-fold 
cross-validation on the dataset to determine the 
hyperparameters of the proposed model. During the model 
training, the loss function is calculated according to the result 
of the forward propagation of each batch of training data. Then 
the parameters of the model are updated using the gradient 
descent method. This process uses a learning rate to define the 
amplitude of each parameter update. If the learning rate is low, 
it will reduce the speed of network optimization and increase 
training time. On the contrary, if the learning rate is high, it may 
cause network parameters to swing back and forth on both 
sides of the optimal value, resulting in network convergence. 
The section adopts an effective method to set the learning rate 
that decays according to the number of iterations. The number 
of the epoch is set to 100. The model performance on AD 
phenotype prediction is evaluated by 10-fold cross-validation. 
As shown in Figure 2, accuracies of three classic machine 
learning methods, SVM, KNN, and BPNN, are relatively low. 
These methods are unable to meet the needs of clinical 
medicine. The proposed method is consistently better than 
three classic machine learning methods, SVM, KNN, and BPNN.  
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Figure 2: Performance comparison of the proposed 
method, SVM, KNN, and BPNN on AD diagnosis. 
3.2.1 Comparison of the prediction performance on the data 
before and after using feature selection. Figure 3 and Figure 4 
indicate that the AD diagnosis performance of the proposed 
model based on the selected 20 signaling proteins is 
comparable with the performance using 120 signaling proteins. 
The accuracy of both were greater than 90%, which is 
significantly better than that of traditional machine learning 
methods. Therefore, the identification of a small group of 
signaling proteins in this paper can reduce model complexity 
and data collection expenses while achieving high diagnostic 
performance. 
 
 
Figure 3: The AD diagnostic error based on 120 signaling 
proteins. 
 
Figure 4: The AD diagnostic error based on the selected 20 
signaling proteins. 
3.2.2 Identifying ACRP30, a risk marker in AD. This paper 
utilizes the hidden layer of the DBN model to learn a high-level 
feature representation of the signal proteins. The DBN model 
then uses these features to complete AD diagnosis tasks. On the 
other hand, this paper can also use these feature 
representations to reconstruct the raw expression values of 
signaling proteins. The proposed method uses the 
reconstruction error to adjust parameters of the prediction 
model for a better diagnosis performance, which calculated by 
the difference between the raw expression values and the high-
level feature representation. Meanwhile, the optimization of 
the model for minimum reconstruction error in the training 
process can help learn a compact and AD-specific feature 
representation with as much raw information as possible. The 
optimal parameters of the model can learn the best feature 
representation with the smallest error. This section uses the 
average reconstruction error to evaluate the effectiveness of 
model training and the reliability of feature transformation. If 
the average reconstruction error of the trained model is small, 
it indicates that the learned high-level feature representation is 
credible. On the contrary, if the error is high, it indicates that 
the trained model cannot learn the high-quality feature 
representation. The learned model does not fit the data well. 
This paper minimizes the average reconstruction error by 
adjusting the number of hidden layer nodes. Figure 5 shows 
that the average reconstruction error is below 0.05 in the 100 
epochs. This low error rate indicates that the model is well 
trained and can learn desired high-level features. Figure 6 
shows AD diagnostic error based on expression values of 120 
signaling proteins in the second model. 
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Figure 5: Average reconstruction error based on 120 
signaling proteins in the second model. 
 
Figure 6: The AD diagnostic error based on 120 signaling 
proteins in the second model. 
This paper attempts to identify the relevant biomarkers and 
determine the etiology of AD by constructing a compact deep 
model that has little hidden nodes. The model self-learned 
some features hidden in the original data in an unsupervised 
way. When the training process of the DBN completes, we gain 
information on the weights of the connections between the 
nodes from adjacent layers. These weights indicate the 
contribution of the nodes to the final prediction results. Figure 
7 shows the visualization of the weights between nodes of the 
input layer and nodes of the hidden layer. 
 
 
Figure 7: Visualization of the weights between nodes of the 
input layer and nodes of the hidden layer. 
For each level, this paper creates a gray-level image by 
mapping the weights to gray levels such that darker gray levels 
are for lower weights. A key advantage of having barcode 
images is that they provide an intuitive, informative, and global 
view of genomes, from which the importance of various genes 
becomes immediately apparent. 
The horizontal and vertical axes represent the number of 
first hidden layer nodes and the type of gene expression data, 
respectively, comprising a 120×5 weight matrix. It is worth 
noting that the brightest line in the picture is the sixty-first, 
which corresponding to the ACRP30. This finding indicates that 
there is a strong association between ACRP30 and AD, which 
may help establish an early diagnosis marker of AD. These 
findings are consistent with previous hypotheses, reinforcing 
the role of adipokines in the pathological mechanism of AD. 
Figure 8 shows the scores of five proteins, including ACRP30, 
TIMP-2, HGF, Eotaxin, and IGFBP-1. ACRP30 gets the highest 
score.  
 
Figure 8: The calculated importance scores of 5 proteins.  
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Correlation is a statistical measure used to assess the degree 
of linear correlation between two continuous variables. The 
correlation coefficient, a dimensionless quantity with the 
values between -1 and 1, is used to indicate the strength of the 
correlation. The value of the correlation coefficient is 0, 
indicating that there is no linear correlation between variables. 
If the correlation coefficient between variables is -1 or 1, it 
means that there is a perfect linear correlation. Any value 
between -1 and 1 can represent the strength of the correlation. 
The stronger the correlation, the closer the absolute value of 
the correlation coefficient is to 1. This paper calculates the 
Spearman’s correlation coefficient to compare with the 
proposed feature selection method. Table 2 indicates that the 
Spearman’s correlation coefficient between ACRP30 and AD is 
0.048. The two-tailed P-value is 0.523. It indicates that the 
correlation is not significant. Thus, ACRP30 and AD have no 
linear correlation relationship and suggest that the proposed 
feature selection method can detect some associations, while 
the Spearman’s correlation coefficients cannot. 
Table 2. Spearman’s correlation coefficient between 
ACRP30 and AD. 
Correlation 
 
ACRP30 AD 
Spearman's rho ACRP30 Correlation coefficient 1.000 .048 
Sig. (2-tailed) . .523 
N 180 180 
AD Correlation coefficient .048 1.000 
Sig. (2-tailed) .523 . 
N 180 180 
4 Biological explanation 
ACRP30 is the most abundant adipocytokine in plasma in many 
forms [39]. As a circulating protein, it is synthesized in adipose 
tissue and there is no clear evidence that it is produced in the 
brain. ACRP30 plays a central regulatory role in energy 
homeostasis. Also, some researches have validated ACRP30’ 
neuroprotective role [40, 41]. Researchers suspect that ACRP30 
may have multiple roles in neurodegenerative disorders, 
including AD. Juhyun concludes that it controls the microglia 
function of the brain [42]. As a surrogate marker, decreased 
adiponectin/ ACRP30 level could indicate AD pathological 
changes and links clinical comorbidities, inflammation, and 
cognitive dysfunction [43]. The process of receptor activation 
stimulates the intracellular catabolism of ceramide [44]. Many 
clinical studies have explored its role in AD pathology, but have 
not reached a consistent conclusion. There are pieces of 
evidence that AD patients have a lower adiponectin level than 
healthy people [57]. However, it does not have the prediction 
ability of dementia progression [45].  
In addition to the direct regulation of the disease, ACRP30 also 
controls the disease indirectly by regulating other factors that 
affect the pathogenesis. Credible researches have shown that 
the accumulation of amyloid-β peptide (Aβ) is a critical marker 
in the pathogenic process of AD. ACRP30 could reduce Aβ 
generation and accumulation [46]. ACRP30 could also improve 
insulin resistance in the central nervous system [47], prevent 
nerve cell apoptosis [48, 49], vascular atherosclerosis, and 
regulate glycolipid metabolism [50, 51]. In the Japanese 
population, a scientific paper shows that serum adiponectin 
level positively correlates with HDL-cholesterol [52]. The 
clinical study has shown that the high plasma cholesterol level 
is a risk factor for AD [53]. However, the cholesterol-AD 
hypothesis presents some difficulties. There is no consensus 
that the cholesterol level in plasma is indicative of cholesterol 
metabolism in AD brains. Some studies have reported that 
there is no relation between serum cholesterol levels and AD. 
Our results provide counterevidence in support of a link.  
Several epidemiological studies have linked obesity to AD 
[54], but the role of adiposity across the course of cognitive 
decline is not well-understood to date. Coronary artery disease 
patients have low plasma adiponectin levels. Moreover, some 
people have suggested an association between 
hypoadiponectinemia and carotid atherosclerosis [58]. The 
present study demonstrates that the plasma adiponectin level 
is positively related to sex, HDL-cholesterol, and BMI. Therefore, 
based on the results of this paper, there is a significant 
indication that cholesterol is an AD risk marker. 
ACRP30 has a direct or indirect regulatory effect on the AD 
pathological process. This paper designs a new feature 
selection method to support this finding from the perspective 
of data science. Therefore, it can serve as a useful therapeutic 
target to alleviate AD manifestations. 
5 Conclusions 
This paper uses a novel method based upon DBN to advance the 
understanding of AD diagnosis as it relates to blood plasma 
protein levels. Even more important than the precision of this 
method is its generalizability. Due to the influence of the 
structural characteristics of DBN, it is convenient to learn the 
nature of expression data automatically and promising for 
medical applications in the era of big data. This paper proposes 
a feature selection algorithm that ranks the features according 
to the weight in a deep network. The size of the feature subset 
can be set variably according to the balance of the diagnostic 
accuracy and complexity of data collection. Thereby, the 
potential correlation between ACRP30 and AD has been 
demonstrated using computational science for the first time 
and suggests its potential biological significance. The 
experiments suggest that the proposed method is significantly 
better than classical machine learning classification methods, 
including KNN, SVM, and BPNN. One can obtain similar 
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forecasting performance using a subset of features, which 
significantly reduces the number of indicators that must be 
collected to predict the disease.  
The proposed feature selection method offers the potential 
to overcome the problems of traditional approaches with 
feature dimensionality and limited size data sets. This method 
also simplifies the measurement index required for diagnosis. 
One could select a subset of factors based on the expected 
diagnostic accuracy. This paper shows ACRP30 to be a causative 
factor in AD both by unsupervised and deep learning methods. 
However, the study also demonstrated that obesity and 
cholesterol are risk factors for AD. These results enhance the 
genetic knowledge of AD and point out that apidonectin-linked 
pathways could be a therapeutic drug target. 
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